{
  "docId": "019de076-e431-717d-85d5-60fbb8c86744",
  "docSlug": "9614dd2dbfdf83d72e770ebfe5753af3",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 38,
  "pageCount": 42,
  "prevPage": 37,
  "nextPage": 39,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "The slide outlines a multi-cohort study design with specific patient populations (TKI-naive vs pre-treated) and objectives.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-e431-717d-85d5-60fbb8c86744/38",
  "deckHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744",
  "deckJsonHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json",
  "deckAnchorHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-38",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.06,
        "y": 0.55
      },
      "kind": "list",
      "text": "Enrollment planned across North America, Europe, Asia and Australia. All patients receive NVL-520 at 100 mg QD. Primary Objective: ORR by blinded, independent central review. Secondary Objectives: Additional efficacy measures (DOR, TTR, CBR, PFS, OS), intracranial activity, overall safety and tolerability, confirmation of PK profile, PROs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4297fdb4-faa7-489a-821f-df787cc81bef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.06,
        "y": 0.3
      },
      "kind": "paragraph",
      "text": "ARROS-1 for TKI-naïve and TKI pre-treated ROS1+ NSCLC (N ≈ 225). Ongoing global open-label, multi-cohort Phase 2 with registrational intent.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f89f4282-3110-410d-89a8-db1901756d87",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.58,
        "x": 0.37,
        "y": 0.83
      },
      "kind": "source-note",
      "text": "1L, 1st line; 2L, 2nd line; CBR, clinical benefit rate; DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression free survival; PK, pharmacokinetics; PRO, patient reported outcomes; QD, once daily; TKI, tyrosine kinase inhibitor; TTR, time to response. a Approximate cohort size, subject to change; b Either crizotinib or entrectinib; c Platinum-based chemotherapy with or without immunotherapy; d With initial TKI of either crizotinib or entrectinib; e Includes NSCLC who do not qualify for any of the other cohorts.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd4a5f51-d46a-466f-9c62-5222e7742fc1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.58,
        "x": 0.37,
        "y": 0.27
      },
      "kind": "table",
      "text": "ARROS-1 Phase 2: Opportunity for approval in both 2L+ and 1L",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16c6596d-22bc-457b-8c2e-527e90771745",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "title",
      "text": "Ongoing ARROS-1 Phase 2 supports goal of moving up the treatment paradigm",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "692f25a0-18b7-42d2-bf5d-1b0aba61dd10",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.11
      },
      "kind": "title",
      "text": "Clinical Development Strategy for ROS1+ NSCLC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d4fb9d2-e3f9-4411-a554-76334aaf205b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "Clinical Trial Design",
      "slug": null,
      "matchId": "df8928dd-5424-486f-a7ad-b52e85923181",
      "evidence": "Multi-cohort study structure with registrational intent",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}